Matrixx Initiatives, Inc. v. Siracusano

Supreme Court of the United States · 2011 · Corporations

563 U.S. 27 (2011)

Updated August 1, 2026

Corporationsmaterialitystatistical significancesecurities fraudRule 10b-5§ 10(b)material omissionscienter

Facts

Matrixx's leading product, Zicam Cold Remedy, allegedly accounted for about 70 percent of its sales. Before and during the class period, Matrixx received reports from medical professionals about more than 10 patients who lost their sense of smell after using Zicam, was told of prior studies linking intranasal zinc to loss of smell, learned of a planned medical presentation on the issue, and faced product liability suits alleging the same causal link. Despite that information, Matrixx publicly projected strong revenue growth and later issued a press release stating that claims that Zicam caused anosmia were completely unfounded and misleading, while citing clinical trials that had not addressed anosmia. Investors alleged these statements were misleading because Matrixx omitted material facts necessary to make them not misleading.

Issue

Can plaintiffs state a § 10(b) and Rule 10b-5 claim based on a pharmaceutical company's failure to disclose adverse event reports even when the reports do not show a statistically significant number of adverse events? Did the complaint adequately plead both materiality and scienter without alleging that Matrixx knew of statistically significant evidence of causation?

Rule

Materiality under § 10(b) and Rule 10b-5 turns on whether there is a substantial likelihood that disclosure of the omitted fact would have been viewed by a reasonable investor as significantly altering the total mix of information available. Adverse event reports are evaluated through a fact-specific inquiry into their source, content, and context; statistical significance may be relevant but is not dispositive, and disclosure is required only when necessary to make statements already made not misleading. Scienter is adequately pleaded under the PSLRA when the complaint states with particularity facts giving rise to a strong inference of the required state of mind that is cogent and at least as compelling as any opposing inference.

🔒

See the holding & full analysis

Create a free KwikCourt account to unlock the rest of this brief — and practice the case.

The court's holding and reasoning
Doctrine tests, pitfalls & exam hypotheticals
10 practice questions + 4 AI-graded essays on this case

Free sample · practice this case

Test yourself

One of 10 multiple-choice questions for this case. Pick an answer to see why.

North Valley Therapeutics, based in Phoenix, sells an over-the-counter migraine spray that generates most of its revenue. Before issuing a press release calling online reports that the spray causes sudden vision loss "baseless," the company had received case reports from two ophthalmologists describing 14 patients with immediate vision problems after use, learned of an upcoming presentation at a national eye-medicine conference, and reviewed published articles discussing a biologically plausible mechanism, but it had no statistically significant study.

If investors sue under Rule 10b-5 based on the omission of those reports, which is the strongest argument that the complaint adequately pleads materiality?

Explanation. The governing rule is Basic's total-mix standard, applied through a fact-specific inquiry into the source, content, and context of the reports. The Court rejected a bright-line statistical-significance requirement. Here, detailed reports from medical professionals, temporal proximity, a planned national medical presentation, published literature suggesting a biological link, and the product's importance to revenue together plausibly suggest materiality. The mere existence of reports is not enough, but more than bare anecdotes can be material even without statistically significant proof.